Unlocking the Therapeutic Potential: Intravenous Glutamine Therapy

Speciality: Emergency Medicine


Speaker:

Dr. Paul Wischmeyer | Professor in University of Colorado school of medicine

Description:

A warm welcome to all the medical professionals in this interesting session on the potential benefits of intravenous glutamine therapy.

Intravenous (IV) glutamine therapy has garnered attention for its potential therapeutic benefits in various clinical settings. Glutamine, an amino acid, plays a crucial role in numerous physiological processes, including protein synthesis, immune function, and cellular metabolism. 

IV administration of glutamine bypasses the digestive system, allowing for rapid absorption and delivery of this essential nutrient directly into the bloodstream. This method is particularly beneficial for patients with conditions such as critical illness, sepsis, and intestinal failure, where oral intake may be compromised or insufficient. IV glutamine supplementation aims to replenish depleted glutamine stores, support immune function, and promote tissue repair and recovery in critically ill patients.

The use of IV glutamine therapy extends beyond critical care settings, with emerging evidence suggesting potential benefits in other clinical scenarios. For example, IV glutamine has shown promise in reducing chemotherapy-induced mucositis and improving outcomes in patients undergoing bone marrow transplantation. 

Therefore, get an overall knowledge on the understanding of the potential benefits of intravenous glutamine therapy. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Virtual Reality Travel Reduces Cancer Pain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot